Determinants of reduced health-related quality of life in pediatric inherited neuropathies
- PMID: 20733147
- PMCID: PMC2931653
- DOI: 10.1212/WNL.0b013e3181eee496
Determinants of reduced health-related quality of life in pediatric inherited neuropathies
Abstract
Objective: We have shown that health-related quality of life (QOL) in children with inherited neuropathies (Charcot-Marie-Tooth disease [CMT]) is significantly reduced compared to population norms, thus establishing its utility as an outcome measure in therapeutic trials. However, the Australian ascorbic acid trial in children with CMT type 1A (CMT1A) identified no change in QOL scores despite a trend toward improvement in nerve conduction velocities in the treated group. The objective of this study was to identify clinical, electrophysiologic, and functional correlates of QOL in children with CMT1A, to guide future investigations of strategies to improve QOL and reduce disability in these patients.
Methods: In this cross-sectional study, a series of multivariate regression models were developed to determine whether QOL scores could be explained by demographic and symptom data, standardized measures of gross motor function, foot/ankle and hand/finger involvement, electrophysiology, and gait characteristics in 70 children aged 5-16 years with CMT1A.
Results: Independent determinants of reduced QOL in children with CMT1A, from strongest to weakest, were leg cramps, hand tremor, short step length, reduced long jump distance, ankle inflexibility, poor agility and endurance, advancing age, and foot drop. Many of the standardized clinical and electrophysiologic measures used as endpoints in clinical trials of CMT correlated poorly with QOL.
Conclusion: QOL is negatively affected by CMT1A in children. Multivariate modeling suggests that interventions designed to improve leg cramps, tremor, agility, endurance, and ankle flexibility might have a substantial effect on QOL in children with CMT1A.
Similar articles
-
Phenotypic Variability of Childhood Charcot-Marie-Tooth Disease.JAMA Neurol. 2016 Jun 1;73(6):645-51. doi: 10.1001/jamaneurol.2016.0171. JAMA Neurol. 2016. PMID: 27043305 Free PMC article.
-
Effect of pain in pediatric inherited neuropathies.Neurology. 2014 Mar 4;82(9):793-7. doi: 10.1212/WNL.0000000000000173. Epub 2014 Jan 29. Neurology. 2014. PMID: 24477108 Free PMC article.
-
Muscle cramp in pediatric Charcot-Marie-Tooth disease type 1A: prevalence and predictors.Neurology. 2011 Dec 13;77(24):2115-8. doi: 10.1212/WNL.0b013e31823d76aa. Epub 2011 Nov 30. Neurology. 2011. PMID: 22131544 Free PMC article.
-
Charcot-Marie-Tooth disease and related inherited neuropathies.Medicine (Baltimore). 1996 Sep;75(5):233-50. doi: 10.1097/00005792-199609000-00001. Medicine (Baltimore). 1996. PMID: 8862346 Review.
-
Walking and weakness in children: a narrative review of gait and functional ambulation in paediatric neuromuscular disease.J Foot Ankle Res. 2020 Mar 2;13(1):10. doi: 10.1186/s13047-020-0378-2. J Foot Ankle Res. 2020. PMID: 32122377 Free PMC article. Review.
Cited by
-
Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis.Sci Rep. 2024 Nov 18;14(1):28394. doi: 10.1038/s41598-024-79918-7. Sci Rep. 2024. PMID: 39551862 Free PMC article.
-
Physical and Mental Aspects of Quality of Life in Patients With Charcot-Marie-Tooth Disease Type 1A.Front Neurol. 2022 Mar 16;13:852150. doi: 10.3389/fneur.2022.852150. eCollection 2022. Front Neurol. 2022. PMID: 35370888 Free PMC article.
-
Development and Validation of the Pediatric Charcot-Marie-Tooth Disease Quality of Life Outcome Measure.Ann Neurol. 2021 Feb;89(2):369-379. doi: 10.1002/ana.25966. Epub 2020 Dec 7. Ann Neurol. 2021. PMID: 33222249 Free PMC article.
-
Outcome measures for Charcot-Marie-Tooth disease: clinical and neurofunctional assessment in children.J Peripher Nerv Syst. 2011 Sep;16(3):237-242. doi: 10.1111/j.1529-8027.2011.00357.x. J Peripher Nerv Syst. 2011. PMID: 22003938 Free PMC article.
-
Prospective study of muscle cramps in Charcot-Marie-tooth disease.Muscle Nerve. 2015 Apr;51(4):485-8. doi: 10.1002/mus.24333. Epub 2015 Feb 11. Muscle Nerve. 2015. PMID: 25042364 Free PMC article. Clinical Trial.
References
-
- Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth disease. Clin Genet 1974;6:98–118. - PubMed
-
- Burns J. Ryan MM, Ouvrier RA. Quality of life in children with Charcot-Marie-Tooth disease. J Child Neurol 2010;25:343–347. - PubMed
-
- Ramchandren S, Shy ME, Finkel RS. Quality of life in children with CMT type1A. Lancet Neurol 2009;8:880–881. - PubMed
-
- Burns J, Ouvrier RA, Yiu EM, et al. Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurol 2009;8:537–544. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases